Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP727360.RAAK4-jpvhdZ1j5e6480dSlyMFj-izSrMeDG43pjN9ZNc130_provenance.
• NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP492276.RAv8vxlfa3Ax3-kS5IZlERGwfIB6Uk1pP1XIJul7MJd-M130_provenance.
• NP466524.RAi4PAmgil8Oi62dBjZIW-uedo2MrDZ3fL3ICo_F9GbPE130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP466524.RAi4PAmgil8Oi62dBjZIW-uedo2MrDZ3fL3ICo_F9GbPE130_provenance.
• NP762431.RAbMYwZ_sy4hxoTZHd6FXPVBn4IwmyAqp3TthUCncPNvg130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP762431.RAbMYwZ_sy4hxoTZHd6FXPVBn4IwmyAqp3TthUCncPNvg130_provenance.
• NP590057.RAyxdbIv0PrpXM13uE8xiAdiYPeQcvNk6hHfvPL-h6PoE130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP590057.RAyxdbIv0PrpXM13uE8xiAdiYPeQcvNk6hHfvPL-h6PoE130_provenance.
• NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP748606.RA48y8Y8o7cNuZp7Sf-w1MxAT6EiUZgqR824a8SAD4VC4130_provenance.
• NP625507.RAb5ZNAZnpo-mOD7zL_TMeJ84mb2p1RALaAApKEBUAaNc130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625507.RAb5ZNAZnpo-mOD7zL_TMeJ84mb2p1RALaAApKEBUAaNc130_provenance.
• NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624457.RAbhHTkfHL1bs4MQH3UxSlVq-UJLKcL7Sq038P0oUmjqU130_provenance.
• NP739557.RAO5t-CQUGjnYDierImY5yqOXDIskq6RciSj_65fjnaqE130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP739557.RAO5t-CQUGjnYDierImY5yqOXDIskq6RciSj_65fjnaqE130_provenance.
• NP787526.RASIRBM6wGIUYVW5pS6PshoKXaXscvlXzC0A9ViQ5ojxg130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP787526.RASIRBM6wGIUYVW5pS6PshoKXaXscvlXzC0A9ViQ5ojxg130_provenance.
• NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP787532.RAVQwygKpaI_v6Dy5J3iLQQ6OfMvOnN8MsLZ8hR8tTsbc130_provenance.
• NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP669703.RAIFf5S29Mz5EGLJyifWhAhxeAJPhgYp-q-vB1reb-TGY130_provenance.
• NP621823.RAuqtyqsaNMq_IjZ5NcNli5yDEV0UrZWu6DyCeqaPr4gY130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621823.RAuqtyqsaNMq_IjZ5NcNli5yDEV0UrZWu6DyCeqaPr4gY130_provenance.
• NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621972.RApU9LOxJw30l5YZ-BhRdDW-VWw-SxsN_DOF6rc691cQg130_provenance.
• NP623051.RAoNH0CAAKLRSiLHHr4CnEQjhXJHR-BIwkAekKE3zr5SA130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623051.RAoNH0CAAKLRSiLHHr4CnEQjhXJHR-BIwkAekKE3zr5SA130_provenance.
• NP787533.RAoREH97dWopNvogP0YDuifCgmJabBNjA0DQdKJzLQLKc130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP787533.RAoREH97dWopNvogP0YDuifCgmJabBNjA0DQdKJzLQLKc130_provenance.
• NP623141.RA4V8tczjkjNY-q4urE0UxchxntMB-Y5YPIk5f5JPYe5k130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623141.RA4V8tczjkjNY-q4urE0UxchxntMB-Y5YPIk5f5JPYe5k130_provenance.
• NP624367.RA2WTmjBaOqaGQARZK-qZIL9YFvJEvIhRCHu9lVqCU3_8130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624367.RA2WTmjBaOqaGQARZK-qZIL9YFvJEvIhRCHu9lVqCU3_8130_provenance.
• NP625598.RAwPRcBxLEVqAnpeGIh9weFxXeoT_bGLfGGC7hIX7dB30130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625598.RAwPRcBxLEVqAnpeGIh9weFxXeoT_bGLfGGC7hIX7dB30130_provenance.
• NP787527.RALx-YUWljQf_gjQp68RxzqcF6lHXBXRJEHFpvVRmlDJE130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP787527.RALx-YUWljQf_gjQp68RxzqcF6lHXBXRJEHFpvVRmlDJE130_provenance.
• NP787528.RA906N1RdKOSqtu0igSZRky1CnKTvFI77ZwUfaEqzQk8o130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP787528.RA906N1RdKOSqtu0igSZRky1CnKTvFI77ZwUfaEqzQk8o130_provenance.
• NP787529.RA7AOuSl9-LQHzWwNyIRrX6Kuh5bxbDcgS-98DI6OSIPk130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP787529.RA7AOuSl9-LQHzWwNyIRrX6Kuh5bxbDcgS-98DI6OSIPk130_provenance.
• NP787530.RA3mEbYemivBILvYJl2FFSQu_DsdErJfXAOCyYPzuwIjk130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP787530.RA3mEbYemivBILvYJl2FFSQu_DsdErJfXAOCyYPzuwIjk130_provenance.
• NP787531.RAy5OI3i-vkl5RMpjD37sV0rgtiRloMNCoOLJ27M8QHDU130_assertion description "[Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP787531.RAy5OI3i-vkl5RMpjD37sV0rgtiRloMNCoOLJ27M8QHDU130_provenance.